Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review

FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)(1) Substantial unmet need exists among patients with METex14 ... Biopharmaceuticals, Oncology Novartis, capmatinib, METex14, NSCLC, lung cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news